RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company, announced on Wednesday that its United States joint venture (JV) partner and licensee, HLB Therapeutics (HLBT), is planning to expand its ophthalmic clinical development program with RGN-259 in two indications, Neurotrophic Keratopathy (NK) and Dry Eye Disease (DED), from November 2022.
The United States joint venture, ReGenTree, LLC, will be sponsoring the trials.
HLBT said, 'Although we at ReGenTree had focused on dry eye clinical trials in recent years, we now plan to run both DED and NK clinical development program simultaneously. In the case of DED, for which ReGenTree conducted a pre-BLA meeting in February this year, we plan to apply for SPA (Special Protocol Assessment) to the FDA around this October. SPA is a program in which FDA specialists provide a sponsor (ReGenTree) with collaboration in setting up clinical protocols and statistical analysis plans. The agreed clinical trial design with FDA is binding and this program will give the sponsor and FDA a clear understanding [of relevant trial criteria] by participating together at this stage of the clinical trial protocol development.'
Sanofi's Nexviadyme gets EU approval in Pompe disease
Ceruvia Lifesciences' synthetic psilocybin Phase two clinical trial receives US FDA approval
Ipsen agrees to acquire Epizyme
ImmuPharma reports Avion seeking final FDA guidance ahead of Phase 3 trial of Lupuzor
Daewoong Pharmaceutical's IND for DWN12088 receives FDA approval for phase two clinical trial
Investigational Lenacapavir Receives Positive CHMP Opinion for People with Multi-Drug Resistant HIV